Mackenzie Financial Corp Keros Therapeutics, Inc. Transaction History
Mackenzie Financial Corp
- $71.6 Billion
- Q2 2025
A detailed history of Mackenzie Financial Corp transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 53,877 shares of KROS stock, worth $839,403. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,877Holding current value
$839,403% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KROS
# of Institutions
156Shares Held
38.6MCall Options Held
834KPut Options Held
969K-
Adar1 Capital Management, LLC Austin, TX5.39MShares$84 Million11.03% of portfolio
-
Madison Avenue Partners, LP New York, NY2.69MShares$41.9 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.63MShares$41 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.6MShares$40.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.51MShares$39.2 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $401M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...